LASTING SKIN HEALING

NEMLUVIO heals nodules to clear the skin in PN1

Image of an actual 31­-year­-old female patient at baseline with prurigo nodularis nodules on back and arms. Image of an actual 31­-year­-old female patient at baseline with prurigo nodularis nodules on back and arms.
Image of an actual 31­-year­-old female patient at Week 16 with healed prurigo nodularis nodules on back and arms. Image of an actual 31­-year­-old female patient at Week 16 with healed prurigo nodularis nodules on back and arms.
 

Baseline

Week 16

31-YEAR-OLD FEMALE.
Actual patient.
Individual results 
may vary.

31-YEAR-OLD FEMALE.
Actual patient. Individual results may vary.

Photo altered to remove identifying marks.

Image of an actual 73­-year­-old male patient at baseline with raised bumps and nodules before NEMLUVIO® (nemolizumab­-ilto) treatment for prurigo nodularis (PN). Image of an actual 73­-year­-old male patient at baseline with raised bumps and nodules before NEMLUVIO® (nemolizumab­-ilto) treatment for prurigo nodularis (PN).
Image of an actual 73­-year­-old male patient with reduced raised bumps and nodules after NEMLUVIO® (nemolizumab­-ilto) treatment for prurigo nodularis (PN). Image of an actual 73­-year­-old male patient with reduced raised bumps and nodules after NEMLUVIO® (nemolizumab­-ilto) treatment for prurigo nodularis (PN).
 

Baseline

Week 16

73-YEAR-OLD MALE.
Actual patient.
Individual results 
may vary.*

73-YEAR-OLD MALE.
Actual Patient. Individual results may vary.*

Image of an actual 43­-year­-old female patient at baseline with raised bumps and nodules before NEMLUVIO® (nemolizumab­-ilto) treatment for prurigo nodularis (PN). Image of an actual 43­-year­-old female patient at baseline with raised bumps and nodules before NEMLUVIO® (nemolizumab­-ilto) treatment for prurigo nodularis (PN).
Image of an actual 43­-year­-old female patient with reduced raised bumps and nodules after NEMLUVIO® (nemolizumab­ilto) treatment for prurigo nodularis (PN). Image of an actual 43­-year­-old female patient with reduced raised bumps and nodules after NEMLUVIO® (nemolizumab­ilto) treatment for prurigo nodularis (PN).
 

Baseline

Week 16

43-YEAR-OLD 
FEMALE.
Actual patient.
Individual results 
may vary.

43-YEAR-OLD FEMALE.
Actual patient. Individual results may vary.

 

31-year-old female.

73-year-old male.

43-year-old female.

REVIEW STUDY DESIGN    

*Baseline IGA score was 4, and at Week 16, it had improved to 2.5

Previous

Next

>75%

of nodules healed in more than half of patients taking NEMLUVIO by Week 16 vs 17% with placebo (P<0.0001)1*

Data above from OLYMPIA 2. In OLYMPIA 1, 41% of patients taking NEMLUVIO achieved >75% nodule healing* vs 12% with placebo at Week 16.1,2

8 out of 10 patients saw >75% of nodules healed with over a year of treatment3

Line graph showing continued skin healing over 68 weeks with NEMLUVIO®.
Line graph showing continued skin healing over 68 weeks with NEMLUVIO®.

Data from observed cases in OLYMPIA 2 treat-through population, interim analysis of the OLYMPIA LTE.
No imputations for missing data. In the full population, 79% of patients (n=313) achieved PAS item 5b improvement at Week 52. The OLYMPIA LTE is an ongoing prospective, multicenter, single-arm, open-label study up to 184 weeks.3,4

REVIEW STUDY DESIGN 

Sleep Improvement1

Patients saw meaningful improvements in their sleep while taking NEMLUVIO1

VIEW THE DATA 

Favorable Safety Profile5

NEMLUVIO offers a favorable safety profile and requires no preliminary lab evaluations or ongoing lab monitoring5

REVIEW SAFETY PROFILE 

IMPORTANT SAFETY INFORMATION

INDICATIONS: NEMLUVIO® (nemolizumab-ilto) is an interleukin-31 receptor alpha antagonist indicated for:

  • the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.
  • the treatment of adults with prurigo nodularis.

CONTRAINDICATION: NEMLUVIO is contraindicated in patients with known hypersensitivity to nemolizumab-ilto or to any of the excipients in NEMLUVIO.

WARNINGS AND PRECAUTIONS:
Hypersensitivity reactions have been reported with NEMLUVIO use. If clinically significant hypersensitivity reaction occurs, immediately institute appropriate therapy, and discontinue NEMLUVIO. Avoid use of live vaccines during treatment with NEMLUVIO.

ADVERSE REACTIONS:
Most common adverse reactions (incidence ≥1%) are:

  • Atopic Dermatitis: headache (including migraine), arthralgia, urticaria, and myalgia. 
  • Prurigo Nodularis: headache, dermatitis atopic, eczema, and eczema nummular. 

USE IN SPECIFIC POPULATIONS:
Pregnancy: There are no adequate and well-controlled studies on NEMLUVIO in pregnant women. The limited available information on NEMLUVIO use during pregnancy is not sufficient to inform a drug- associated risk of major birth defects or miscarriage in humans. Human IgG antibodies are known to cross the placental barrier; therefore, NEMLUVIO may be transmitted from the mother to the developing fetus.

Lactation: There are no data on the presence or transfer of NEMLUVIO in human milk, the effects on the breastfed infant, or the effects on milk production. Human IgG is known to be present in human milk. The effects of local gastrointestinal and limited systemic exposure to NEMLUVIO on the breastfed infant are unknown. NEMLUVIO has not been administered to nursing/lactating women. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NEMLUVIO and any potential adverse effects on the breastfed child from NEMLUVIO or from the underlying maternal condition.

Pediatric Use: The safety and effectiveness of NEMLUVIO have not been established in pediatric patients younger than 12 years of age for the treatment of moderate-to-severe atopic dermatitis or pediatric patients younger than 18 years of age for the treatment of prurigo nodularis.

Please see full Prescribing Information, including Patient Information.